{"doi":"10.3390/cancers15123179","title":"Stratification of Tamoxifen Synergistic Combinations for the Treatment of ER+ Breast Cancer","abstract":"Breast cancer alone accounts for the majority of cancer deaths among women, with the most commonly diagnosed subtype being estrogen receptor positive (ER+). Survival has greatly improved for patients with ER+ breast cancer, due in part to the development of antiestrogen compounds, such as tamoxifen. While treatment of the primary disease is often successful, as many as 30% of patients will experience recurrence and metastasis, mainly due to developed endocrine therapy resistance. In this study, we discovered two tamoxifen combination therapies, with simeprevir and VX-680, that reduce the tumor burden in animal models of ER+ breast cancer more than either compound or tamoxifen alone. Additionally, these tamoxifen combinations reduced the expression of HER2, a hallmark of tamoxifen treatment, which can facilitate acquisition of a treatment-resistant phenotype. These combinations could provide clinical benefit by potentiating tamoxifen treatment in ER+ breast cancer.","journal":"Cancers","year":2023,"id":364076,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":7,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9456,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":704350,"name":"Jacqueline M. Grible","orcid":null,"position":1,"is_corresponding":false},{"id":571567,"name":"David C. Boyd","orcid":"0000-0002-9422-830X","position":2,"is_corresponding":false},{"id":732553,"name":"Nicole S. Hairr","orcid":"0000-0002-9128-1690","position":3,"is_corresponding":false},{"id":732555,"name":"Tess J. Leftwich","orcid":"0000-0002-5586-5023","position":4,"is_corresponding":false},{"id":1118828,"name":"Mathew Esquivel","orcid":"0000-0002-7744-7316","position":5,"is_corresponding":false},{"id":1118829,"name":"Alex Duong","orcid":"0000-0002-8138-0943","position":6,"is_corresponding":false},{"id":1106605,"name":"Scott A. Turner","orcid":"0000-0002-5545-9738","position":7,"is_corresponding":false},{"id":1107053,"name":"Andrea Ferreira‐Gonzalez","orcid":null,"position":8,"is_corresponding":false},{"id":571568,"name":"Amy L. Olex","orcid":"0000-0001-8064-521X","position":9,"is_corresponding":false},{"id":292451,"name":"Carol A. Sartorius","orcid":"0000-0002-9170-3988","position":10,"is_corresponding":false},{"id":265858,"name":"Mikhail G. Dozmorov","orcid":"0000-0002-0086-8358","position":11,"is_corresponding":false},{"id":292566,"name":"J. Chuck Harrell","orcid":"0000-0003-3541-8418","position":12,"is_corresponding":false},{"id":989925,"name":"Emily K. Zboril","orcid":null,"position":0,"is_corresponding":true}],"reference_count":64,"raw_metadata":null,"created_at":"2026-07-19T01:14:36.728255Z","pmid":"37370789","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}